# Carter BloodCare – FDA Inspection, Jun 14, 2023

Source: https://www.keypedia.com/records/fda_inspections/carter-bloodcare/182c01b4-a170-47d0-9fa0-1467ac05e837
Source feed: FDA_Inspections

> FDA inspection 1210114 of Carter BloodCare, June 14, 2023. Classification: No Action Indicated (NAI). 6 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1210114
- Company Name: Carter BloodCare
- Inspection Date: 2023-06-14
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1257853 - 2024-12-04
- FDA Inspection 1063657 - 2018-08-15
- FDA Inspection 963720 - 2016-01-13
- FDA Inspection 865335 - 2014-02-04
- FDA Inspection 770786 - 2012-03-05

## Related Officers

- [Company Rep](https://www.keypedia.com/people/kaarin-m-slotte/2960bbe1-17ba-4295-9aa8-2514a1595336)

Company: https://www.keypedia.com/companies/carter-bloodcare/a54c2982-1796-4788-b533-2369461510e8

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d